Ahmed Mousa
Chief Executive Officer Vicore Pharma Holding
Ahmed Mousa has an extensive background in business and corporate development, portfolio strategy, and entrepreneurial experience in the life sciences industry. Prior to joining Vicore, Ahmed was the Chief Business Officer & General Counsel of Pieris Pharmaceuticals where he played a key role in development of the company’s pipeline and execution of strategic collaborations with a range of pharmaceutical companies. Ahmed previously was an attorney representing biopharmaceutical companies in a range of matters at Covington & Burling and Kirkland & Ellis.
Seminars
Wednesday 2nd December 2026
From Epithelial Repair to Durable Benefit: AT2 Receptor Agonism as an Upstream Intervention in Fibrotic Disease
12:00 pm
- AT2 receptor agonism restores the protective arm of the renin–angiotensin system, promoting epithelial resilience and repair following alveolar injury – an early pathogenic event that can contribute to inflammation, metabolic dysfunction, vascular remodelling, and fibrosis
- Positioning the AT2 receptor as an upstream modulatory node at the intersection of fibrotic remodelling: where diverse pathological insults converge on shared profibrotic pathways, while disease-specific biology defines therapeutic opportunity and indication boundaries
- Translational evidence for AT2 receptor agonism in fibrotic disease in preclinical and early clinical studies
Wednesday 2nd December 2026
Panel Discussion: Defining Cross-Indication Expansion Strategies to Maximize the Clinical & Commercial Potential of Antifibrotic Therapies
2:30 pm
- Determining when preclinical evidence is sufficiently robust to justify expanding an antifibrotic program into additional fibrotic indications rather than remaining disease-specific
- Identifying the biological, translational, regulatory, and commercial factors that should guide indication prioritization, including shared mechanisms, biomarker availability, clinical endpoints, and unmet need
- Exploring whether future antifibrotic programs should be intentionally designed as multi-indication assets from discovery or whether expansion should remain a staged, indication-by-indication strategy
